Metabolic Health: A Comprehensive Guide to Understanding Obesity & Diabetes

Understand the effects of obesity and diabetes on overall wellness and take steps towards improvement in your metabolic health.

Abstract

Hello, I’m Dr. Alex Jimenez. In this educational post, we will embark on a comprehensive journey to understand the intricate and often overlapping physiological pathways of obesity, type 2 diabetes, and cardiovascular disease. I will present a patient-centered, first-person narrative describing how I approach these conditions through an integrative lens that blends chiropractic care, functional medicine, medical oversight, and rehabilitation. Drawing on the latest evidence-based research from leading experts, we will explore why treating obesity is not a matter of willpower but of addressing deep-seated biological dysregulation. We will delve into how inflammation, insulin resistance, and hormonal imbalances form a common pathological foundation for these chronic conditions. This discussion will highlight how modern pharmacotherapy targets these underlying mechanisms and why a chronic disease management model is essential for long-term success. Furthermore, I will explain how our unique multidisciplinary practice at Injury Medical Clinic PA integrates my chiropractic and functional medicine care with medical direction from our collaborative physician to provide a holistic and powerful treatment strategy for patients grappling with these complex cardiometabolic issues. We will break down the science, examine treatment guidelines, and illustrate how a synergistic approach, through real-world patient scenarios, can lead to profound improvements in health and quality of life.

Our Integrative Team: A Multidisciplinary Powerhouse

At Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas, our philosophy is rooted in collaboration and integration. We believe that the most effective patient care comes from combining the strengths of different medical disciplines. I am Dr. Alexander Jimenez, and my credentials as a Doctor of Chiropractic (DC), Advanced Practice Registered Nurse (APRN), board-certified Family Nurse Practitioner (FNP-BC), and advanced certifications in Functional Medicine (CFMP, IFMCP, ATN, CCST) allow me to view patient health through a multifaceted lens. My focus is on the structural, neurological, and functional aspects of wellness.

A cornerstone of our practice is our collaboration with Dr. Maria Guadalupe Cardenas, MD. Dr. Cardenas is Board Certified in Internal Medicine with an impressive 40 years of experience (NPI #1164426749, Texas MD License #J2933). She serves as our Medical Director and Collaborative Physician, providing invaluable medical oversight, ensuring our protocols are evidence-based, and offering a deep understanding of internal medicine. This partnership between a chiropractor and an internist allows us to create a truly comprehensive care model, which is a standard and effective setup in integrative and injury care clinics.

Our team works in synergy to address the full spectrum of a patient’s needs. Here’s how our services fit together:

• Medical Oversight (Dr. Cardenas, MD): Dr. Cardenas guides our medical protocols, confirms diagnoses, manages complex internal medicine conditions, reviews contraindications, and provides the necessary supervision for prescription therapies and advanced medical interventions. Her extensive experience is crucial for diagnosing and treating systemic diseases that often accompany musculoskeletal issues, such as diabetes and cardiovascular disease.
• Chiropractic & Functional Medicine (Dr. Jimenez, DC, APRN, FNP-BC): I focus on restoring the body’s natural function. Through chiropractic adjustments, we can improve nervous system function, reduce pain, and enhance mobility. This is particularly important for patients with obesity, as pain can be a major barrier to physical activity. Through functional medicine, we dive deep to identify the root causes of dysfunction—be it gut dysbiosis, hormonal imbalances, or nutrient deficiencies—and create personalized plans involving nutrition, supplementation, and lifestyle changes to restore health from the inside out.
• Rehabilitation & Personal Injury Care: Our team also includes specialists in physical rehabilitation who help patients recover from injuries and improve their functional capacity. This is a critical component of managing obesity, as structured exercise programs are essential for building muscle, improving metabolism, and supporting weight loss.

By integrating these disciplines, we don’t just treat symptoms; we treat the whole person. We address the structural, biochemical, and medical aspects of health simultaneously, providing a level of care far more effective than any single approach could be.

Understanding the Roots of Cardiometabolic Disease

In my clinical practice, we frequently manage conditions like dyslipidemia (abnormal blood fats), hypertension (high blood pressure), and various metabolic disorders. For decades, we have had a wide array of medications to manage the symptoms of these diseases. However, a crucial understanding has emerged from modern research: in many cases, obesity is the underlying root cause of these interconnected health problems.

Imagine a tree. The branches and leaves—the visible parts—are the diseases we commonly treat, such as heart disease, diabetes, and high blood pressure. But the roots, hidden beneath the surface, represent the foundational issue of obesity. These are the obesity-related complications and comorbidities that drive the majority of chronic diseases we face today.

The Misconception of Willpower: Obesity Causes Overeating

The human body possesses remarkably resilient, tightly regulated systems. If you become dehydrated, your kidneys conserve water, and you feel thirsty, prompting you to drink. In the same way, body weight is meant to be tightly regulated. However, in obesity, this regulatory system becomes dysfunctional. A groundbreaking shift in our understanding is this: Overeating doesn’t cause obesity; obesity causes overeating. Before a noticeable increase in fat mass (adiposity) occurs, a dysregulation of the endocrine system is already underway.

• The First Hit: Hormonal Dysregulation
• The process begins when something—be it genetics, environmental factors, or obesogenic medications—triggers the “on” switch for obesity. Once activated, the body’s production of hunger hormones (like ghrelin) increases, while the production of satiety hormones (like leptin and GLP-1) decreases. This creates a powerful biological drive for increased hunger and food intake.
• The Second Hit: The Brain Defends a Higher Weight
• The second, and perhaps more insidious, part of this pathology is that the brain begins to defend this new, higher body weight as its “normal.” This is the biological reality behind the frustrating cycle of weight regain. We now know it’s a consequence of dysregulated biology. The leading hypothesis is that this defense mechanism arises from inflammation in the hypothalamus, the brain’s control center for appetite and energy expenditure.

Obesity is an incredibly multifactorial disease, influenced by over 200 genes, endocrine-disrupting chemicals, poor sleep, and chronic stress.

The Pathophysiological Overlap of Diabetes and Heart Disease

To truly appreciate the interconnected nature of these conditions, let’s look at the underlying biology of each.

The Progression of Type 2 Diabetes

The pathophysiology of type 2 diabetes unfolds over years, beginning with insulin resistance, where cells become less responsive to insulin. To compensate, the pancreatic beta cells work overtime, producing more insulin. Eventually, these cells become exhausted, leading to impaired insulin secretion and elevated blood sugar (hyperglycemia), a condition known as prediabetes. As function declines further, type 2 diabetes is diagnosed. Beyond the pancreas, diabetes involves chronic inflammation, gut dysbiosis, and mitochondrial dysfunction, which contribute to “metabolic memory,” perpetuating the disease.

The Inflammatory Core of Cardiovascular Disease

Cardiovascular disease shares a similar common denominator: atherosclerosis, the buildup of plaque in the arteries, which is fundamentally driven by inflammation. A key player is nitric oxide (NO), a critical molecule that promotes vasodilation (widening of blood vessels) and reduces inflammation. In cardiovascular disease, nitric oxide availability decreases, leading to increased blood clotting, rampant inflammation, and endothelial dysfunction (damage to blood vessel linings). Metabolically, this leads to decreased glucose tolerance, elevated triglycerides, and increased oxidative stress.

The Unifying Theory: Inflammation, Lipotoxicity, and Mitochondrial Dysfunction

A clear picture emerges when we put it all together. The journey often begins with obesity, which fosters chronic inflammation and lipotoxicity (cellular damage from excess fats). This environment leads to mitochondrial dysfunction, impairing cellular energy production. This trifecta—inflammation, lipotoxicity, and mitochondrial dysfunction—creates a vicious cycle, driving the progression of obesity, insulin resistance, type 2 diabetes, and ultimately, cardiovascular disease.

Patient Journey: Stephen’s Case and Early Intervention for Prediabetes

To illustrate these concepts, let’s look at a patient I’ll call Stephen. His journey highlights how we apply this integrative model in practice.

Case Introduction and Risk Profile

Stephen is a 24-year-old male who sees me for follow-up regarding prediabetes and weight management. His A1C is 5.8%. He has a history of progressive weight gain, reaching a current weight of 250 lb with a BMI of 32.1 (class I obesity). His family history is significant for obesity, cardiovascular disease, and type 2 diabetes. His exam reveals central adiposity with a waist circumference of 41 inches, acanthosis nigricans, and skin tags, all signs of chronic hyperinsulinemia and insulin resistance.

From a physiological standpoint, Stephen exhibits a classic metabolic phenotype driven by:

• Visceral adiposity: Central fat secretes pro-inflammatory adipokines and reduces adiponectin, impairing insulin sensitivity.
• Hepatic insulin resistance: Increased liver glucose production and dyslipidemia, increasing his risk of metabolic dysfunction-associated steatotic liver disease (MASLD).
• Endocrine signals: Altered leptin signaling and dysregulated GLP-1/GIP pathways that reduce satiety.
• Biomechanics: Excess abdominal load increases lumbar lordosis and knee strain, areas where chiropractic integrative care can provide structural relief.

Evidence-Based Weight Loss Targets: Why Percentages Matter

I explained to Stephen that targeted weight-loss thresholds can dramatically change his health trajectory:

• 3% weight loss: Measurable improvements in prediabetes and insulin sensitivity.
• 10% weight loss: Robust changes in glucose control, lipids, and blood pressure.
• 15%+ weight loss: Meaningful impact on type 2 diabetes, dyslipidemia, hypertension, sleep apnea, and MASLD.

Reducing adipose tissue lowers inflammatory cytokines, restores hormonal balance, and improves insulin signaling. These targets guide our decision on whether to use lifestyle changes alone or incorporate anti-obesity pharmacotherapy.

Patient Journey: Victoria – The Intersection of Menopause, Weight Gain, and Diabetes

Now, let’s explore a case representative of what many women experience during menopause.

Initial Presentation and History

Victoria, a 52-year-old woman, came to my clinic for a follow-up on her prediabetes and recent weight gain. She had recently entered menopause and gained 15 pounds in the past year. Her job is largely sedentary, her activity level has decreased, and she suffers from poor sleep due to night sweats.

Key Clinical Details:

• BMI: 31.8 (class 1 obesity)
• Fat Distribution: Central adiposity, with a neck circumference of 16 inches, a risk factor for sleep apnea.
• Symptoms: Hot flashes, snoring, and high stress.

The Menopausal Transition and Metabolic Disruption

Victoria’s case is a classic example of the metabolic storm that accompanies menopause. The decline in estradiol leads to a rise in LDL cholesterol, decreased insulin sensitivity, a shift toward increased body fat, and endothelial dysfunction. These changes amplify cardiovascular risk. Fortunately, menopause hormone therapy (MHT) can mitigate many of these risks.

Laboratory Findings and Diagnosis

Victoria’s lab work confirmed our concerns. Her HbA1c had risen to 7.3%, diagnosing her with type 2 diabetes. Her HOMA-IR score, a measure of insulin resistance, was 4.7, indicating significant dysfunction.

Crafting a Patient-Centered Treatment Plan

Using a shared decision-making model, I asked Victoria, “What area would you like to target first?” She chose to try a higher dose of metformin and was intrigued by the idea of using a Continuous Glucose Monitor (CGM). The CGM provides invaluable real-time feedback that drives positive behavior changes. We also referred her to a menopause specialist.

When Victoria returned, her CGM data was eye-opening. Her average glucose was 173 mg/dL, and she was spending 34% of her time in hyperglycemia. Armed with this new insight, she committed to increasing her metformin, boosting protein intake, and eliminating sugar-sweetened beverages. A month later, after starting MHT, her sleep and hot flashes improved, but her weight loss was slow. At this point, I introduced semaglutide, a GLP-1 receptor agonist. One year later, she had lost 25 pounds, her BMI dropped from 31.8 to 27.5, and her metabolic markers improved dramatically. By treating her obesity, we achieved remission of her diabetes.

Patient Journey: Banny – Addressing Long-Standing Diabetes and Cardiovascular Risk

Our next case involves Banny, a 64-year-old man with a long and complex medical history, including type 2 diabetes for 25 years, hypertension, and a previous heart attack. His weight was 230 lbs (BMI of 36), and he struggled with food cravings and uncontrolled blood pressure.

The “5 C’s” of Obesity Treatment

When evaluating Banny, I used my “5 C’s” framework: Criteria, Contraindications, Combine, Cues/Causes, and Cost/Coverage. His history of cardiovascular disease made him a prime candidate for a GLP-1 receptor agonist like semaglutide, which has been shown to reduce the risk of major adverse cardiovascular events. I framed it as a way to not only manage his diabetes and weight but also reduce his risk for a second heart attack. He was immediately on board.

Uncovering Hidden Liver Disease

Banny’s labs showed a slightly elevated liver enzyme (ALT), prompting me to calculate his FIB-4 score, a non-invasive screen for liver fibrosis. His score of 2.25 placed him at high risk. This is critical, as up to 65% of people with type 2 diabetes have Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). I referred him to a gastroenterologist for further evaluation.

One year later, Banny had lost 23 pounds, and his HbA1c improved to 5.9%. He was diagnosed with liver fibrosis and started on a new medication. However, his weight loss had plateaued, and he struggled with intense food cravings. To address this, we added a low dose of topiramate at night to help control cravings, demonstrating a multi-pronged approach to modern obesity management.

Chiropractic Care & Metabolism *The Hidden Link*- Video

A Unified Approach to Treatment: Beyond “Eat Less, Move More”

The treatment guidelines for obesity, diabetes, and cardiovascular disease share a common foundation: a healthy eating plan, increased physical activity, and behavioral interventions. For diabetes and heart disease, we readily use medications, yet for obesity, there’s a misguided notion that patients must first “fail” lifestyle changes. This ignores the biological reality of the disease, where metabolic adaptation fiercely defends a higher body weight. Medications for obesity directly counteract the pathological hormonal and neurological changes driving the disease.

Nutrition Strategy: Creating Sustainable Metabolic Change

For patients like Stephen, we design a sustainable, enjoyable nutrition plan. This includes:

• Caloric reduction: A deficit of 500- 750 kcal daily.
• Carbohydrate management: Moderating refined carbs to improve insulin signaling.
• Protein prioritization: To support satiety, thermogenesis, and muscle retention.
• Fiber and non-starchy vegetables: To improve glycemic control and gut microbiome diversity.

Behavioral Health Strategy: Sleep, Stress, and Mood

Chronic stress and poor sleep worsen insulin resistance and weight gain by increasing cortisol and altering ghrelin and leptin levels. We screen for and address stress, mood, and sleep disorders, such as sleep apnea.

Physical Activity: Graded Movement and Functional Capacity

I provide evidence-based recommendations, such as 150-300 minutes/week of moderate-intensity activity and resistance training at least two days a week. For patients with pain, we incorporate referrals to physical and occupational therapy.

The Role of Modern Medications

The advent of GLP-1 receptor agonists (like liraglutide and semaglutide) and dual GIP/GLP-1 agonists (like tirzepatide) has been a game-changer. These medications mimic the body’s natural satiety hormones, helping patients achieve an average weight loss of 15-20% or more. Excitingly, many of these newer drugs, along with SGLT-2 inhibitors, have demonstrated significant cardiovascular benefits.

Recent multi-year research on tirzepatide has shown it can sustain a diabetes-free status in adults with prediabetes and deliver high-magnitude weight loss. For Stephen, after reviewing his options, we selected tirzepatide, starting at 2.5 mg weekly and titrating up. Two weeks later, he had lost 3 lbs. At one year, after reaching a 15 mg weekly dose, he had lost 50 lbs, his A1C was 5.4%, and his BMI dropped to 25.7.

An important part of my job is also avoiding obesogenic medications—drugs like certain sulfonylureas, insulins, and beta-blockers that can cause weight gain.

Chiropractic Integration: How Structural Care Supports Metabolic Therapy

While pharmacological and lifestyle interventions are central, integrative chiropractic care is a foundational element of our holistic approach.

• Stress Reduction and Nervous System Regulation: Chronic stress is a major driver of metabolic dysfunction. My clinical observations show that patients with central obesity often develop thoracolumbar junction stiffness. Chiropractic adjustments can influence the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This modulation can lower physiological stress, supporting better glycemic control (Jimenez, n.d.-a).
• Improving Mobility and Reducing Pain: For patients like Stephen, Victoria, and Banny, joint pain and stiffness can be significant barriers to physical activity. By performing spinal and extremity adjustments, we can improve joint function, reduce pain, and make it easier for patients to engage in regular exercise. This facilitates adherence to activity prescriptions.
• Optimizing Biomechanics: Correcting thoracolumbar junction dysfunction and sacroiliac joint mechanics can improve gait efficiency and reduce the energy cost of movement, making it easier for patients to increase their daily steps (Jimenez, n.d.-b).
• Enhancing Sleep Quality: Alleviating neck and upper back tension can support airway mechanics and reduce nocturnal discomfort, which, in my clinical experience, can improve morning glucose stability.

The Chronic Disease Model: Why Treatment Must Be Long-Term

I want to end by reinforcing the most crucial concept: obesity is a chronic, relapsing disease that requires long-term management. The pathology of weight regain is a biological certainty, not a personal failing. When a person with obesity loses weight, the brain initiates a powerful counter-response: metabolism slows down, hunger hormones surge, and satiety hormones decrease. This creates an overwhelming drive to regain weight.

The STEP 1 trial extension starkly illustrates this: when participants stopped taking semaglutide, they began regaining weight, and their blood pressure and A1C levels started to creep back up (Wilding et al., 2022). We must apply the same chronic care model to obesity that we use for hypertension or diabetes. The goal is sustainable, long-term management to control the disease and prevent its devastating complications.

At Injury Medical Clinic, this philosophy guides us. By integrating chiropractic care to restore function, functional medicine to address root causes, and medical oversight from Dr. Cardenas to leverage the best of modern pharmacotherapy, we provide our patients with the comprehensive, long-term support they need to conquer these interconnected diseases and reclaim their health.

---

SEO Tags: Obesity Treatment, Type 2 Diabetes, Prediabetes Management, Cardiovascular Disease, Integrative Care, Chiropractic, Functional Medicine, Tirzepatide, GLP-1 GIP Agonists, Dr. Alex Jimenez, Dr. Maria Cardenas, El Paso Clinic, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Inflammation, Insulin Resistance, Metabolic Adaptation, Weight Regain, Cardiometabolic Health, Chronic Disease Management, Atherosclerosis, Nitric Oxide, Pharmacotherapy, Menopause and Weight Gain, Continuous Glucose Monitor, Semaglutide

---

References

• American Diabetes Association. (2024). Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1).
• Endocrine Society. (2020). Clinical Guidelines for Obesity Management in Adults.
• Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., Regensteiner, J., Venditti, B., & Wylie-Rosett, J. (2006). Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care, 29(9), 2102–2107.
• Jimenez, A. (n.d.-a). Dr. Alex Jimenez Clinical Observations. ChiroMed.
• Jimenez, A. (n.d.-b). Dr. Alex Jimenez Professional Profile. LinkedIn.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., Steinberg, W. M., Stockner, M., Zinman, B., Bergenstal, R. M., Buse, J. B., & LEADER Steering Committee. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, 375(4), 311–322.
• Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A. A. (2022). The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 7(9), 851–861.
• Rubino, D. M., et al. (2022). Obesity Pharmacotherapy and GLP-1/GIP Agonists: Mechanisms and Outcomes. New England Journal of Medicine.
• Ryan, D. H., Lingvay, I., Deanfield, J., Sharma, A. M., & SELECT Trial Investigators. (2024). The SELECT trial: Semaglutide and cardiovascular outcomes in obesity without diabetes. Obesity, 32(1), 16-19.
• U.S. Department of Health and Human Services. (2018). Physical Activity Guidelines for Americans, 2nd Edition.
• Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Mosenzon, O., Pedersen, S. D., TSK, R., Sjöström, C. D., Wadden, T. A., & Rubino, D. M. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553-1564.
• Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., & Wagenknecht, L. (2011). Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care, 34(7), 1481–1486.